- Eve & Co (TSXV:EVE) subsidiary Natural MedCo has received its European Union “Good Manufacturing Practice” certification
- The Government of Upper Bavaria in Germany granted the certification
- Natural MedCo is one of only a few Canadian companies with a EU GMP certification for cannabis
- Eve & Co’s share price is up 36.84 per cent, and is currently trading at $0.13 per share
Female-led cannabis company Eve & Co (TSXV:EVE) has announced that its subsidiary, Natural MedCo, has received EU GMP certification.
The European Union ‘Certificate of GMP Compliance of a Manufacturer” was granted by the Government of Upper Bavaria in Germany.
GMP (Good Manufacturing Practice) certification is an essential stamp of approval that Natural MedCo had to obtain in order to start fulfilling supply agreements.
The company made great efforts to ensure that its manufacturing standards, production practices, and products were consistently high-quality. Company employees also had to have an adequate amount of experience in order to meet the standard.
Having satisfied EU GMP requirements, Natural MedCo is one of the few Canadian companies with EU GMP certification for cannabis. It almost certainly has the first Canadian female-led cannabis facility with an EU GMP certification.
Eve & Co President and CEO, Melinda Rombouts, said she was very happy with the achievement.
“I attribute this accomplishment to the hard work of our team and their dedication to ensuring our facility complies with the most stringent standards. This certification enables us to continue in our global growth strategy and fulfil contracts in the EU market,” she said.
“With our 1 million square foot licensed greenhouse, we hope to set ourselves apart as one of the largest cannabis facilities in the world. We will also do so with our ability to distribute our products in a much larger global marketplace, “Melinda added.
Eve & Co’s share price is up 36.84 per cent, and is trading at $0.13 per share, as of 1:04pm EST.
